Philips reiterates timing of 2026 outlook

Rhea-AI Summary

Royal Philips (NYSE: PHG) reaffirmed on 4 December 2025 that its 2026 outlook will be published on 10 February 2026 as previously scheduled. The company said it expects continued performance improvement with sequential comparable sales growth, expanded margins despite tariff headwinds, and strong cash flow.

Philips reiterated an expectation that comparative sales growth will accelerate sequentially in 2026 toward mid-single-digit growth, supported by solid order momentum and consistent with the last four quarters. The company has not released an early view of formal guidance and will share its full outlook on 10 February 2026.

December 4, 2025

Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today reaffirmed that its 2026 outlook will be issued as planned on February 10, in line with the company’s previously communicated schedule.

As previously guided, the company expects continued performance improvement with sequential comparable sales growth, expanded margins (despite tariff headwinds) and strong cashflow. The company continues to expect comparative sales growth to accelerate sequentially in 2026 towards mid-single-digit growth in line with the current trajectory and supported by continued solid order momentum. This is in line with performance in the last four consecutive quarters.

The company has not released any early view of its forthcoming guidance. Yesterday at an industry conference, in answer to a question, the company confirmed that sequential acceleration towards mid-single-digit growth continues to be its expectation and noted this does not imply doubling growth every single year in the company’s multi-year trajectory.

Philips will share its outlook as part of its planned disclosure on February 10.

For further information, please contact:

Steve Heywood
Philips Global External Relations
Tel.: +31 638 363 589
E-mail: steve.heywood@philips.com

Dorin Danu
Philips Investor Relations
Tel.: +31 205 977 055
E-Mail: dorin.danu@philips.com

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home.

Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2024 sales of EUR 18 billion and employs approximately 67,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

FAQ

When will Philips (PHG) publish its 2026 outlook?

Philips will publish its 2026 outlook on 10 February 2026.

What growth does Philips (PHG) expect for 2026?

Philips expects sequential acceleration toward mid-single-digit comparative sales growth in 2026.

Did Philips (PHG) provide early guidance for 2026 on December 4, 2025?

No, Philips confirmed it has not released any early view of its formal 2026 guidance.

What operating trends did Philips (PHG) reiterate for 2026?

Philips reiterated expectations for expanded margins (despite tariff headwinds) and strong cash flow alongside sales acceleration.

Does Philips (PHG) say the mid-single-digit goal implies doubling growth each year?

No, the company noted that sequential acceleration toward mid-single-digit growth does not imply doubling growth every year.